A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration

Michael E. Burton, Cynthia L. Ash, Donald P. Hill, Ta Ree Handy, Marvin D. Shepherd, Michael R. Vasko

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


We studied the effect of a bayesian pharmacokinetic dosing program on the outcome of aminoglycroside therapy in patients with clinical infections. Patients were randomized to a control (dosing based on physician choice; n = 75) or experimental group (dosing based on the bayesian program; n = 72). Both groups used serum ammoglycoside concentration data when maid dosing decisions. Improved response rates were seen in the experimental (60%; 42168) compared with the control group (48%; 36 68). A higher, but not statistically significant, incidence of toxicity was found in the control ( 7 75; 9.7%) versus the experimental group ( 4 72; 5.1%). Mean length of total hospital stay was significantly longer for patients in the control group (20.3 days) compared with the experimental group (16.0 days) (p = 0.028). The variables from multivariate analysis with a significant impact on length of stay were patient group and length of ammoglycoside therapy. On the basis of a reduced length of stay, a potential cost savings of $1311 per patient can be achieved .

Original languageEnglish (US)
Pages (from-to)685-694
Number of pages10
JournalClinical Pharmacology and Therapeutics
Issue number6
StatePublished - Jun 1991

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A controlled trial of the cost benefit of computerized bayesian aminoglycosde administration'. Together they form a unique fingerprint.

Cite this